GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LifeTech Scientific Corp (HKSE:01302) » Definitions » EBIT

LifeTech Scientific (HKSE:01302) EBIT : HK$120 Mil (TTM As of Jun. 2024)


View and export this data going back to 2011. Start your Free Trial

What is LifeTech Scientific EBIT?

LifeTech Scientific's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was HK$168 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was HK$120 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. LifeTech Scientific's annualized ROC % for the quarter that ended in Jun. 2024 was 9.08%. LifeTech Scientific's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 23.53%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. LifeTech Scientific's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 2.15%.


LifeTech Scientific EBIT Historical Data

The historical data trend for LifeTech Scientific's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LifeTech Scientific EBIT Chart

LifeTech Scientific Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 212.57 318.07 410.85 422.88 192.84

LifeTech Scientific Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 234.95 199.04 240.80 -47.96 168.40

Competitive Comparison of LifeTech Scientific's EBIT

For the Medical Devices subindustry, LifeTech Scientific's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LifeTech Scientific's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, LifeTech Scientific's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where LifeTech Scientific's EV-to-EBIT falls into.



LifeTech Scientific EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$120 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LifeTech Scientific  (HKSE:01302) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

LifeTech Scientific's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=336.796 * ( 1 - 10.95% )/( (3316.14 + 3291.622)/ 2 )
=299.916838/3303.881
=9.08 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5136.784 - 530.737 - ( 1289.907 - max(0, 842.358 - 2440.377+1289.907))
=3316.14

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5188.471 - 775.641 - ( 1121.208 - max(0, 889.789 - 2388.438+1121.208))
=3291.622

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

LifeTech Scientific's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=336.796/( ( (1007.876 + max(296.696, 0)) + (1087.881 + max(470.045, 0)) )/ 2 )
=336.796/( ( 1304.572 + 1557.926 )/ 2 )
=336.796/1431.249
=23.53 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(115.049 + 528.957 + 488.165) - (530.737 + 0 + 304.738)
=296.696

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(131.525 + 591.626 + 526.301) - (775.641 + 0 + 3.7660000000001)
=470.045

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

LifeTech Scientific's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2024 )
=120.438/5596.230
=2.15 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LifeTech Scientific EBIT Related Terms

Thank you for viewing the detailed overview of LifeTech Scientific's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


LifeTech Scientific Business Description

Traded in Other Exchanges
Address
No. 22, Keji 12th Road South, LifeTech Scientific Building, High-tech Industrial Park, Nanshan District, Shenzhen, CHN, 518063
LifeTech Scientific Corp develops and manufactures also responsible for marketing of of advanced minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The firm operates in three areas: Structural heart diseases business; Peripheral vascular diseases business and Cardiac pacing and electrophysiology business. It generates maximum revenue from the Peripheral vascular diseases business segment. Geographically, it derives a majority of revenue from China.
Executives
Xie Yuehui 2201 Interest of corporation controlled by you
Xianjian Advanced Technology Limited 2101 Beneficial owner
Hhlr Advisors, Ltd. 2102 Investment manager
Bank Of Communications Trustee Limited 2301 Trustee
Xie Yuehui 2201 Interest of corporation controlled by you
Hhlr Fund, L.p. 2101 Beneficial owner
Hillhouse Capital Advisors, Ltd. 2102 Investment manager
Gaoling Fund, L.p. 2101 Beneficial owner

LifeTech Scientific Headlines

No Headlines